Abstract: Objective To explore the efficacy of entecavir and silibinin combination in the treatment of patients with chronic hepatitis B. Methods 140 patients with chronic hepatitis B were recruited in our hospital between June 2015 and July 2016,and the patients were divided into observation group （n=70） and control group （n=70） by a randomized grouping method. The patients in the control group was treated with entecavir,and the patients in the observation group was treated with entecavir combined with silibinin capsules. The clinical symptoms and signs,negative conversion rates of serum HBeAg and HBV DNA,liver function index,cytokine levels and peripheral blood T lymphocyte subsets were detected and compared between the two groups. Results At the end of 24 w treatment,the improvement of fatigue,anorexia and abdominal distension in the observation group were 87.1%,90%,82.9%,respectively,significantly higher than those in the control group （41.4%,71.4%,58.6%,P<0.05）;the negative rates of serum HBeAg and HBV DNA in the observation group were 0.0% and 88.6%,no statistical difference（P>0.05） as compared to 0.0% and 68.6% in the control group; serum TBIL,ALT and AST levels in the observation group were （16.49±3.17） μmol/L,（47.36±8.24） U/L and （40.58±5.26） U/L,significantly lower than （23.56±3.48） μmol/L,（68.25±7.93） U/L and （66.24±8.24） U/L in the control （P<0.05）;serum IL-6, TNF-α and TGF-β levels in the observation group were （204.8±27.4） μg/L,（68.2±12.5） μg/L and（158.2±15.2） μg/L, significantly lower than （264.2±29.2） μg/L,（107.4±13.7） μg/L and （193.5±17.3） μg/L in the control （P<0.05）;the peripheral blood CD4+ cells and ratio of CD4+/CD8+ in the observation group were （40.36±3.61） % and（1.50±0.32）,significantly higher than （33.46±3.17） % and （1.33±0.27） in the control（P<0.05）. Conclusion Entecavir combined with silibinin capsules in the treatment of patients with chronic hepatitis B have curative effect by the inhibition of HBV replication,relieving the inflammatory reactions,and improving the immune functions.

Key words: Hepatitis B, Entecavir, Silibinin, Therapy